Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029315 · ClinicalTrials.gov registry record · Phase 2
Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage
A Phase 2 study of Cerebral Hemorrhage, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00029315: Completed Phase 2 study of Cerebral Hemorrhage, sponsored by Johns Hopkins University.
NCT00029315 is a Phase 2 study of Cerebral Hemorrhage that has completed, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00029315, a Phase 2 study of Cerebral Hemorrhage, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.
Conditions Studied
Interventions
- DRUG Recombinant Tissue Plasminogen Activator (rt-PA)
Study Locations (1)
Maryland
- The Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
What the finished NCT00029315 record still lists
NCT00029315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Cerebral Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Tissue Plasminogen Activator (rt-PA) is the first listed.
NCT00029315 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00029315 about?
NCT00029315 is a clinical study titled "Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage". This is a study to evaluate how recombinant tissue plasminogen activator (rt-PA) is utilized in patients with intraventricular hemorrhage (IVH). rt-PA is a drug that has been shown to dissolve blood, and may allow intraventricular catheters to be more effective for a longer period of time.
What is the current status of trial NCT00029315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2001-09. Estimated completion is 2004-09.
What conditions does trial NCT00029315 study?
This clinical trial studies the following conditions: Cerebral Hemorrhage.
What interventions are being tested in trial NCT00029315?
The interventions under investigation include: Recombinant Tissue Plasminogen Activator (rt-PA) (DRUG).
Who is sponsoring clinical trial NCT00029315?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00029315 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00029315's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia